User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 3 results.
    • Speech
    Selection based on SAF activity score, not NASH CRN NAFLD activity score, leads to selection of a patient cohort with more severe NASH with more advanced fibrosis: experience from the NATIVE phase 2b study of the PanPPAR agonist lanifibranor
    Francque, Sven Bedossa, Pierre Ratziu, Vlad Anstee, Quentin Bugianesi, Elisabetta Sanyal, Arun Loomba, Rohit Harrison, Stephen A. Balabanska, Rozalina Ivanova Mateva, Lyudmila Lanthier, Nicolas[UCL] (2020) The Liver Meeting Digital Experience —
    • Speech
    The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial
    Francque, Sven Bedossa, Pierre Ratziu, Vlad Anstee, Quentin Bugianesi, Elisabetta Sanyal, Arun Loomba, Rohit Harrison, Stephen A Balabanska, Rozalina Ivanova Mateva, Lyudmila Lanthier, Nicolas[UCL] (2020) The Liver Meeting Digital Experience —
    • Journal article
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
    Francque, Sven M. Bedossa, Pierre Ratziu, Vlad Anstee, Quentin M. Bugianesi, Elisabetta Sanyal, Arun J. Loomba, Rohit Harrison, Stephen A. Balabanska, Rozalina Mateva, Lyudmila Lanthier, Nicolas[UCL] Alkhouri, Naim Moreno, Christophe Schattenberg, Jörn M. Stefanova-Petrova, Diana Vonghia, Luisa Rouzier, Régine Guillaume, Maeva Hodge, Alexander Romero-Gómez, Manuel Huot-Marchand, Philippe Baudin, Martine Richard, Marie-Paule Abitbol, Jean-Louis Broqua, Pierre Junien, Jean-Louis Abdelmalek, Manal F. (2021) New England Journal of Medicine — Vol. 385, no. 17, p. 1547-1558 (2021)